COLOMBO NICOLETTA

Boidot, R., Blum, M., Wissler, M., Gottin, C., Ruzicka, J., Chevrier, S., et al. (2024). Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer. EUROPEAN JOURNAL OF CANCER, 202(May 2024) [10.1016/j.ejca.2024.113978]. Dettaglio

Colombo, N., Lorusso, D., Monk, B., Slomovitz, B., Hasegawa, K., Nogueira-Rodrigues, A., et al. (2024). Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab. THE ONCOLOGIST, 29(1), 25-35 [10.1093/oncolo/oyad201]. Dettaglio

Monk, B., Colombo, N., Tewari, K., Tekin, C., Keefe, S., Lorusso, D. (2024). Reply to P.-H. Luo et al. JOURNAL OF CLINICAL ONCOLOGY [10.1200/JCO.24.00077]. Dettaglio

Betella, I., De Vitis, L., Calidona, C., Multinu, F., Colombo, N. (2024). Letter to the editor-The new FIGO staging system for endometrial cancer: Is the paradigm shift clinically feasible?. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 164(1), 364-365 [10.1002/ijgo.15265]. Dettaglio

Tewari, K., Colombo, N., Monk, B., Dubot, C., Caceres, M., Hasegawa, K., et al. (2024). Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial. JAMA ONCOLOGY, 10(2), 185-192 [10.1001/jamaoncol.2023.5410]. Dettaglio